Full Product Name
ARL6 siRNA (Mouse)
Product Synonym Names
BBS3; ADP-ribosylation factor-like protein 6
Product Gene Name
ARL6 sirna
[Similar Products]
Research Use Only
For Research Use Only. Not for use in diagnostic procedures.
3D Structure
ModBase 3D Structure for O88848
Specificity
ARL6 siRNA (Mouse) is a target-specific 19-23 nt siRNA oligo duplexes designed to knock down gene expression.
Purity/Purification
> 97%
Form/Format
Lyophilized powder
Quality Control
Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.
Directions for Use
We recommends transfection with 100 nM siRNA 48 to 72 hours prior to cell lysis. Before resuspending, briefly centrifuge the tube to ensure the lyophilized siRNA is at the bottom of the tube. Resuspend the siRNA oligos to an appropriate concentration with DEPC water. For each vial, suitable for 250 transfections in 24 well plate (20 pmol for each well).
Components
We offer pre-designed sets of 3 different target-specific siRNA oligo duplexes of mouse ARL6 gene. Each vial contains 5 nmol of lyophilized siRNA. The duplexes can be transfected individually or pooled together to achieve knockdown of the target gene, which is most commonly assessed by qPCR or western blot. Our siRNA oligos are also chemically modified (2'-OMe) at no extra charge for increased stability and enhanced knockdown in vitro and in vivo.
Preparation and Storage
Shipped at 4 degree C. Store at -20 degree C for one year.
Negative Control
siRNA Negative Control (Catalog# MBS8241404) is a non-targeting 21 nt siRNA recommended as a negative control for experiments using targeted siRNA transfection.
Other Notes
Small volumes of ARL6 sirna vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.
Related Product Information for
ARL6 sirna
siRNA to inhibit ARL6 expression using RNA interference
Applications Tested/Suitable for ARL6 sirna
RNA Interference (RNAi)
NCBI/Uniprot data below describe general gene information for ARL6. It may not necessarily be applicable to this product.
NCBI Accession #
NP_062639.3
[Other Products]
NCBI GenBank Nucleotide #
NM_019665.3
[Other Products]
UniProt Primary Accession #
O88848
[Other Products]
UniProt Secondary Accession #
Q3TY77[Other Products]
UniProt Related Accession #
O88848[Other Products]
Molecular Weight
21,778 Da
NCBI Official Full Name
ADP-ribosylation factor-like protein 6
NCBI Official Synonym Full Names
ADP-ribosylation factor-like 6
NCBI Official Symbol
Arl6 [Similar Products]
NCBI Official Synonym Symbols
BBS3; 1110018H24Rik; 2210411E14Rik
[Similar Products]
NCBI Protein Information
ADP-ribosylation factor-like protein 6
UniProt Protein Name
ADP-ribosylation factor-like protein 6
UniProt Gene Name
Arl6 [Similar Products]
UniProt Synonym Gene Names
Bbs3 [Similar Products]
UniProt Entry Name
ARL6_MOUSE
UniProt Comments for ARL6
ARL6: Involved in membrane protein trafficking at the base of the ciliary organelle. Mediates recruitment onto plasma membrane of the BBSome complex which would constitute a coat complex required for sorting of specific membrane proteins to the primary cilia. May regulate cilia assembly and disassembly and subsequent ciliary signaling events such as the Wnt signaling cascade. Isoform 2 may be required for proper retinal function and organization. Defects in ARL6 are a cause of Bardet-Biedl syndrome type 3 (BBS3). Bardet-Biedl syndrome (BBS) is a genetically heterogeneous disorder characterized by usually severe pigmentary retinopathy, early onset obesity, polydactyly, hypogenitalism, renal malformation and mental retardation. Secondary features include diabetes mellitus, hypertension and congenital heart disease. Defects in ARL6 are the cause of retinitis pigmentosa type 55 (RP55). RP55 is a retinal dystrophy belonging to the group of pigmentary retinopathies. Retinitis pigmentosa is characterized by retinal pigment deposits visible on fundus examination and primary loss of rod photoreceptor cells followed by secondary loss of cone photoreceptors. Patients typically have night vision blindness and loss of midperipheral visual field. As their condition progresses, they lose their far peripheral visual field and eventually central vision as well. Belongs to the small GTPase superfamily. Arf family. 2 isoforms of the human protein are produced by alternative splicing.
Protein type: G protein; G protein, monomeric; G protein, monomeric, ARF
Cellular Component: cell projection; cytoskeleton; membrane; cytoplasm; plasma membrane; intracellular; cytosol; cilium
Molecular Function: protein binding; GTP binding; metal ion binding; nucleotide binding
Biological Process: protein transport; protein amino acid ADP-ribosylation; Wnt receptor signaling pathway; cell projection organization and biogenesis; transport; small GTPase mediated signal transduction; Ras protein signal transduction; cilium biogenesis; brain development; intermembrane transport; regulation of smoothened signaling pathway
Disease: Bardet-biedl Syndrome 1
Research Articles on ARL6
1. Results show that BBS1 and BBS3 regulates the ciliary traficking of PC1.
Precautions
All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.
Disclaimer
While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.
It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.
